Depressed cancer survivors are twice as likely to die prematurely than those who do not suffer from depression, irrespective of the cancer site. That's according to a new study, by Floortje Mols and colleagues, from Tilburg University in The Netherlands.
[More]
Loyola University Medical Center has opened a new 20-bed unit for patients undergoing stem cell transplants for cancers such as leukemia, lymphoma and multiple myeloma.
[More]
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.
[More]
A single antibody could be the key to treating multiple myeloma, or cancer of the blood, currently without cure or long-term treatment.
[More]
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.
[More]
Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins.
[More]
Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.
[More]
BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.
[More]
Pharmacyclics, Inc. announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma, (RESONATE) was achieved on April 3, 2013.
[More]
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.
[More]
BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.
[More]
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
[More]
BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.
[More]
A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans.
[More]
Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma patients with deletion of the short arm of chromosome 17 (deletion 17p).
[More]
BioInvent International AB announce that the previously communicated positive results from a phase I trial of BI-505 is presented today at The International Myeloma Workshop in Kyoto, Japan.
[More]
The scientific benefits of whole genome sequencing at the Translational Genomics Research Institute will be presented at the 14th International Myeloma Workshop, April 3-7 at the Kyoto International Conference Center.
[More]
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.
[More]
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
[More]
Eli Lilly and Company presented results today at the annual European Association of Urology Congress in Milan, Italy, of a study that showed Cialis 5 mg once daily co-administered with finasteride significantly improved scores on the International Prostate Symptom Score, compared to placebo/finasteride, in men with lower urinary tract symptoms of benign prostatic hyperplasia and enlarged prostates.
[More]